Overview

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

Samyang Biopharmaceuticals Corporation

Treatments:

Docetaxel